Samuel Minaker, MD
Ophthalmology · Tyler, TXNPI 1174194955
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,504 of the $48,290 with a category attached, or 63.2%. It is spread thinly across 16 manufacturers, the largest accounting for just 22.0%. 2025 is the largest year on record at $27,617, more than ten times the $122 reported in 2021. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $371.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$11K
- Ocular Therapeutix, Inc.$10K
- AbbVie$8K
- Apellis Pharmaceuticals, Inc.$7K
- Alimera Sciences, Inc.$4K
- Harrow Eye, LLC$3K
- plus $5K from 10 others
What the payments were for
- Consulting fees$30,50463%
- Speaking & faculty fees$4,91310%
- Travel & lodging$5,23711%
- Food & beverage$7,63616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 18 | $10,636 |
| Ocular Therapeutix, Inc. | 15 | $10,212 |
| AbbVie | 8 | $7,925 |
| Apellis Pharmaceuticals, Inc. | 23 | $7,113 |
| Alimera Sciences, Inc. | 12 | $4,327 |
| Harrow Eye, LLC | 5 | $2,856 |
| Eyepoint US, Inc. | 6 | $2,307 |
| Astellas Pharma US Inc | 13 | $978 |
| Regeneron Healthcare Solutions, Inc. | 10 | $510 |
| Alcon | 2 | $418 |
| Regeneron | 7 | $373 |
| ANI Pharmaceuticals, Inc. | 5 | $307 |
| Bausch & Lomb Americas Inc. | 2 | $123 |
| Genentech, Inc. | 2 | $111 |
| Samsara Vision | 1 | $59 |
| Coherus Oncology, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,290 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 46 | $2,008 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $153 |
| ErythromycinErythromycin Base | 15 | $145 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Tyler
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.